{"id":52528,"date":"2023-01-04T16:02:13","date_gmt":"2023-01-04T15:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/"},"modified":"2023-01-04T16:02:13","modified_gmt":"2023-01-04T15:02:13","slug":"suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/","title":{"rendered":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform"},"content":{"rendered":"
\n

FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio, the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, today announced the first patient has been dosed with its SuonoCalmTM<\/sup> product. This next-generation treatment leverages the company\u2019s ultrasonic platform for topical and oral delivery of therapeutics to the gastrointestinal tract, including biologics and genetic medicines.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are ecstatic to witness our foundational technology implemented in humans for the first time. This has been years in the making and puts us much closer to our goal of dramatically improving treatment options for serious gastrointestinal diseases and beyond,\u201d said Scott Kellogg, Chief Executive Officer of Suono Bio.\n<\/p>\n

\n\u201cSince we first discovered the ability to deliver unformulated therapeutics, including RNA-based medicines, to the GI tract, the company has worked diligently to de-risk this technology and build out a meaningful pipeline of therapeutic candidates. The initiation of clinical testing begins a new phase for the company and helps serve to prove out not only the SuonoCalmTM<\/sup>, but the broader platform for enabling the oral delivery of biologics and other delicate medicines, the holy grail in drug delivery,\u201d added Professor Robert Langer, co-founder and director of Suono Bio.\u201d\n<\/p>\n

\nThe SuonoCalm is a therapeutic platform for the ultra-rapid administration of a wide range of medicines. The technology is being tested for the topical administration of mesalamine for the treatment of ulcerative colitis and represents Suono Bio\u2019s lead indication. The trial is assessing the safety and tolerability of the treatment, including tissue-level drug concentrations, to inform final treatment protocols. \u201cWe are excited to be leading the first-in-human testing of this new technology, both for its potential promise to address unmet needs for patients with IBD and broader potential impact on GI health,\u201d added Dr. Jake Begun IBD Group Leader at Mater Research University, and Suono Bio Medical Advisory Board member.\n<\/p>\n

\nAbout Suono Bio<\/b>\n<\/p>\n

\nSuono Bio is a clinical-stage company developing novel treatment options to enable the topical and oral delivery of biologics and genetic medicines in a formulation-independent manner. Suono Bio\u2019s platform was developed at The Massachusetts Institute of Technology in Professor Robert Langer\u2019s laboratory and enables rapid, delivery of a wide-range of therapeutic payloads. For more information, please visit www.suonobio.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor and Media Inquiries
\n
info@suonobio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio, the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, today announced the first patient has been dosed with its SuonoCalmTM product. This next-generation treatment leverages the company\u2019s ultrasonic platform for topical and oral delivery of therapeutics to the gastrointestinal tract, including biologics and genetic medicines. \u201cWe … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52528","6":"format-standard","7":"category-industry"},"yoast_head":"\nSuono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio, the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, today announced the first patient has been dosed with its SuonoCalmTM product. This next-generation treatment leverages the company\u2019s ultrasonic platform for topical and oral delivery of therapeutics to the gastrointestinal tract, including biologics and genetic medicines. \u201cWe ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T15:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform\",\"datePublished\":\"2023-01-04T15:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/\"},\"wordCount\":391,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005668\\\/en\\\/1676701\\\/21\\\/Suono_Bio%5B32%5D.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/\",\"name\":\"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005668\\\/en\\\/1676701\\\/21\\\/Suono_Bio%5B32%5D.jpg\",\"datePublished\":\"2023-01-04T15:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005668\\\/en\\\/1676701\\\/21\\\/Suono_Bio%5B32%5D.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005668\\\/en\\\/1676701\\\/21\\\/Suono_Bio%5B32%5D.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/","og_locale":"en_US","og_type":"article","og_title":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend","og_description":"FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio, the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, today announced the first patient has been dosed with its SuonoCalmTM product. This next-generation treatment leverages the company\u2019s ultrasonic platform for topical and oral delivery of therapeutics to the gastrointestinal tract, including biologics and genetic medicines. \u201cWe ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-04T15:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform","datePublished":"2023-01-04T15:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/"},"wordCount":391,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/","url":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/","name":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg","datePublished":"2023-01-04T15:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230104005668\/en\/1676701\/21\/Suono_Bio%5B32%5D.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/suono-bio-inc-announces-first-patient-dosed-with-its-suonocalmtm-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52528"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52528\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}